Symbols / DRMA $1.29 +7.50% Dermata Therapeutics, Inc.
DRMA Chart
About
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.19M |
| Enterprise Value | -2.33M | Income | -7.56M | Sales | — |
| Book/sh | 2.34 | Cash/sh | 1.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 0.09 | Forward P/E | -0.33 | PEG | — |
| P/S | — | P/B | 0.55 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 4.58 |
| Current Ratio | 4.79 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -8.16 | EPS next Y | -3.87 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 17:00 | ROA | -85.25% |
| ROE | -194.20% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.02M |
| Shs Float | 2.93M | Short Float | 1.39% | Short Ratio | 0.02 |
| Short Interest | — | 52W High | 9.90 | 52W Low | 1.10 |
| Beta | 0.50 | Avg Volume | 2.11M | Volume | 158.86K |
| Target Price | $4.00 | Recom | Buy | Prev Close | $1.20 |
| Price | $1.29 | Change | 7.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$1.29
Latest analyst target
3. DCF / Fair value
$-22.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.29
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-21 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-21 | main | Maxim Group | Buy → Buy | $3 |
| 2024-08-21 | main | Maxim Group | Buy → Buy | $6 |
| 2023-03-23 | main | Maxim Group | — → Buy | $4 |
- Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan hu, 02 Apr 2026 12
- $DRMA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 20 Mar 2026 07
- Dermata Therapeutics (DRMA) SVP adds 1,000 shares in insider buy - Stock Titan ue, 17 Mar 2026 07
- Dermata stock surges after closing $4.1 million private placement - Investing.com Mon, 29 Dec 2025 08
- Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo Wed, 01 Apr 2026 14
- Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Stocktwits Wed, 24 Dec 2025 08
- From prescription acne to at-home skincare: Dermata targets 2026 launch - Stock Titan hu, 26 Mar 2026 07
- Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan Wed, 24 Dec 2025 08
- 3.3M Australians with acne: Dermata's new treatment patent - Stock Titan ue, 20 Jan 2026 08
- New Dermata marketing chief to launch Tome skincare line in 2026 - Stock Titan ue, 10 Mar 2026 07
- Skincare firm Dermata raises $4.1M to back new over-the-counter acne kit - Stock Titan Mon, 29 Dec 2025 08
- Dermata Therapeutics (NASDAQ: DRMA) teases OTC brand, plans 2026 acne kit launch - Stock Titan hu, 04 Dec 2025 08
- Dermata (NASDAQ: DRMA) shifts to DTC skincare as 2025 loss shrinks - Stock Titan hu, 26 Mar 2026 21
- Dermata Therapeutics (NASDAQ: DRMA) pivots from Rx acne to Tome OTC skincare - Stock Titan hu, 26 Mar 2026 07
- Dermata (NASDAQ: DRMA) pivots to OTC skincare, plans once-weekly acne kit launch mid-2026 - Stock Titan Fri, 14 Nov 2025 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
7.77
-37.88%
|
12.51
+55.60%
|
8.04
-16.88%
|
9.67
|
| Research And Development |
|
2.93
-64.28%
|
8.20
+101.58%
|
4.07
-27.98%
|
5.65
|
| Selling General And Administration |
|
4.84
+12.39%
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| General And Administrative Expense |
|
—
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| Other Gand A |
|
—
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| Total Expenses |
|
7.77
-37.88%
|
12.51
+55.60%
|
8.04
-16.88%
|
9.67
|
| Operating Income |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Total Operating Income As Reported |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| EBITDA |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Normalized EBITDA |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
—
|
| EBIT |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Pretax Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Non Operating Interest Income Expense |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
-0.06
|
| Net Interest Income |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Expense |
|
—
|
—
|
—
|
-0.06
|
| Interest Income Non Operating |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Income |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income From Continuing And Discontinued Operation |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income Continuous Operations |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Normalized Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income Common Stockholders |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Diluted EPS |
|
—
|
-80.32
+79.91%
|
-399.90
+80.85%
|
-2,088.00
|
| Basic EPS |
|
—
|
-80.32
+79.91%
|
-399.90
+80.85%
|
-2,088.00
|
| Basic Average Shares |
|
—
|
0.15
+684.80%
|
0.02
+323.37%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.15
+684.80%
|
0.02
+323.37%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
—
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.86
+122.53%
|
3.53
-55.71%
|
7.98
+14.89%
|
6.94
|
| Current Assets |
|
7.86
+122.53%
|
3.53
-55.71%
|
7.98
+14.89%
|
6.94
|
| Cash Cash Equivalents And Short Term Investments |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Cash And Cash Equivalents |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Receivables |
|
—
|
—
|
0.01
-33.69%
|
0.01
|
| Other Receivables |
|
—
|
—
|
—
|
0.01
|
| Accrued Interest Receivable |
|
—
|
—
|
0.01
-33.69%
|
0.01
|
| Prepaid Assets |
|
0.34
-8.18%
|
0.37
-31.12%
|
0.54
-21.73%
|
0.69
|
| Current Deferred Assets |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
—
|
—
|
0.01
+24.94%
|
0.01
|
| Total Non Current Assets |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.64
-16.85%
|
1.97
+21.51%
|
1.62
+75.98%
|
0.92
|
| Current Liabilities |
|
1.64
-16.85%
|
1.97
+21.51%
|
1.62
+75.98%
|
0.92
|
| Payables And Accrued Expenses |
|
0.66
-46.74%
|
1.24
+36.82%
|
0.91
+20.59%
|
0.75
|
| Payables |
|
0.46
-42.97%
|
0.81
-6.70%
|
0.87
+74.36%
|
0.50
|
| Accounts Payable |
|
0.46
-42.97%
|
0.81
-6.70%
|
0.87
+74.36%
|
0.50
|
| Current Accrued Expenses |
|
0.20
-53.78%
|
0.43
+953.95%
|
0.04
-83.92%
|
0.26
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.98
+33.87%
|
0.73
+2.11%
|
0.72
+320.50%
|
0.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Common Stock Equity |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Capital Stock |
|
0.00
+964.00%
|
0.00
-3.85%
|
0.00
-66.23%
|
0.00
|
| Common Stock |
|
0.00
+964.00%
|
0.00
-3.85%
|
0.00
-66.23%
|
0.00
|
| Share Issued |
|
3.20
+1170.12%
|
0.25
+860.79%
|
0.03
+410.42%
|
0.01
|
| Ordinary Shares Number |
|
3.20
+1170.12%
|
0.25
+860.79%
|
0.03
+410.42%
|
0.01
|
| Additional Paid In Capital |
|
79.46
+18.18%
|
67.24
+12.54%
|
59.74
+15.75%
|
51.61
|
| Retained Earnings |
|
-73.23
-11.51%
|
-65.68
-23.02%
|
-53.39
-17.10%
|
-45.59
|
| Total Equity Gross Minority Interest |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Total Capitalization |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Working Capital |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Invested Capital |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Net Tangible Assets |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Tangible Book Value |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Interest Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Cash Flow From Continuing Operating Activities |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Net Income From Continuing Operations |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
—
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
—
|
| Other Non Cash Items |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.14
-78.14%
|
0.66
+25.97%
|
0.52
-43.88%
|
0.93
|
| Change In Working Capital |
|
-0.34
-173.41%
|
0.47
-45.94%
|
0.86
+662.38%
|
-0.15
|
| Change In Prepaid Assets |
|
0.03
-81.88%
|
0.17
+3.37%
|
0.16
+33.42%
|
0.12
|
| Change In Payables And Accrued Expense |
|
-0.37
-224.95%
|
0.30
-57.39%
|
0.70
+354.43%
|
-0.28
|
| Change In Accrued Expense |
|
0.01
-96.35%
|
0.41
+22.78%
|
0.33
+229.06%
|
-0.26
|
| Change In Payable |
|
-0.39
-257.62%
|
-0.11
-129.38%
|
0.37
+2091.73%
|
-0.02
|
| Change In Account Payable |
|
-0.39
-257.62%
|
-0.11
-129.38%
|
0.37
+2091.73%
|
-0.02
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
12.12
+75.97%
|
6.89
-9.46%
|
7.61
+77.84%
|
4.28
|
| Cash Flow From Continuing Financing Activities |
|
12.12
+75.97%
|
6.89
-9.46%
|
7.61
+77.84%
|
4.28
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
12.17
+76.72%
|
6.89
-9.47%
|
7.61
+77.85%
|
4.28
|
| Common Stock Payments |
|
-0.00
+55.68%
|
-0.00
-1970.00%
|
-0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
-0.00
+55.68%
|
-0.00
-1970.00%
|
-0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-11.90%
|
0.00
+493.05%
|
0.00
-34.84%
|
0.00
|
| Net Other Financing Charges |
|
-0.05
|
—
|
—
|
—
|
| Changes In Cash |
|
4.36
+201.96%
|
-4.28
-457.32%
|
1.20
+126.26%
|
-4.56
|
| Beginning Cash Position |
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
-42.20%
|
10.80
|
| End Cash Position |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Free Cash Flow |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock Issuance |
|
12.17
+76.70%
|
6.89
-9.46%
|
7.61
+77.85%
|
4.28
|
| Issuance Of Capital Stock |
|
12.17
+76.70%
|
6.89
-9.46%
|
7.61
+77.85%
|
4.28
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-03-17 View
- 8-K2026-02-25 View
- 8-K2026-02-03 View
- 8-K2026-01-27 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-29 View
- 42025-12-29 View
- 8-K2025-12-29 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|